042520 — HANS BIOMED Income Statement
0.000.00%
Last trade - 00:00- KR₩320bn
- KR₩356bn
- KR₩90bn
Annual income statement for HANS BIOMED, fiscal year end - September 30th, KRW millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 59,098 | 74,459 | 78,032 | 81,137 | 89,780 |
| Cost of Revenue | |||||
| Gross Profit | 29,229 | 45,683 | 45,123 | 51,747 | 51,514 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 75,442 | 73,166 | 82,553 | 80,507 | 115,670 |
| Operating Profit | -16,344 | 1,293 | -4,521 | 630 | -25,891 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -21,617 | 3,501 | -23,532 | -6,631 | -29,752 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22,126 | 4,923 | -24,092 | -7,800 | -32,075 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -18,289 | 6,147 | -23,045 | -7,223 | -31,341 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -18,289 | 2,369 | -23,045 | -7,223 | -31,341 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2,053 | 180 | -2,127 | -554 | -1,270 |
| Dividends per Share |